BioCryst Pharmaceuticals Inc (BCRX): EBITDA
$342.38M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $342.38M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$1.30M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$102.05M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$147.00M | n/m | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | -$176.94M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$174.01M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$98.73M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$93.45M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$56.71M | n/m | 2020-03-13, From 2017-01-01 |
| 2016-12-31 | -$48.12M | n/m | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | -$39.26M | n/m | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | -$45.59M | n/m | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | -$30.41M | n/m | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | -$33.26M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | -$48.70M | n/m | 2014-03-10, From 2011-01-01 |
| 2010-12-31 | -$32.09M | n/a | 2013-03-11, From 2010-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $342.38M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $133.91M | +287.5% |
| Novavax Inc (NVAX) | 2025-12-31 | $480.41M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $349.25M | +64.6% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $480.39M | -14.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $199.54M | +35.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$42.25M | n/m |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$2.86B | n/m |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$111.41M | n/m |
Compare BCRX, RGEN, NVAX, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗